Pure H20 Bio-Technologies, Inc. Announces Confirmation of New Stock Symbol PRHB, and Reverse Split of Its Common Stock

  
    
  
  
    
      Pure H20 Bio-Technologies, Inc. (Pink 
      Sheets:PRHB), today announces confirmation of New Stock Symbol PRHB and 
      Reverse Split of its Common Stock. The Company’s 
      stock transfer agent, Continental Stock Transfer and Trust Company, 
      located at 17 Battery Place, New York, New York, is the Exchange Agent 
      for its approved reverse split of the Company's Common Stock. On March 
      3, 2008 the company filed a 1-for-4,500 (1:4,500) reverse stock split of 
      the Company's Common Stock. The reverse split became effective today 
      upon the filing of the company's Certificate of Amendment to the 
      Articles of Incorporation of Pure H20 
      Bio-Technologies, Inc., with the Florida Secretary of State.
    
    
      The reorganization will be effective at the open of the market today and 
      the new stock symbol is "PRHB" and the Cusip Number is: 746223 40 3. The 
      distribution of the post-split common shares are payable upon surrender 
      of the pre-split common shares.
    
    
      "For each forty-five hundred (4,500) shares of pre-split common stock 
      held a shareholder will receive one (1) share of post-split common 
      stock. No fractional shares or script representing fractions of a share 
      shall be issued, but in lieu thereof, each fraction of a share that any 
      Stockholder would otherwise be entitled to receive shall be rounded up 
      to the nearest whole share and no additional script or payment made," as 
      stated in the Company's Articles of Amendment.
    
    
      About PRHB: PRHB is a publicly held company specializing in the 
      research, development and commercialization of its unique residential, 
      commercial and hospital water disinfection systems. The company intends 
      to commence the manufacture and distribution of its products through a 
      network of independent distributors.
    
    
      The foregoing press release contains forward-looking statements that can 
      be identified by such terminology as expects, potential, suggests, may, 
      intends, or similar expressions. Such forward-looking statements involve 
      known risks, uncertainties, and other factors that may cause the actual 
      results to be materially different from any future results, performance 
      or achievements expressed or implied by such statements. In particular, 
      management expectations regarding future research, development, and/or 
      commercial results could be affected by, among other things, 
      uncertainties relating to the availability of future financing, 
      unexpected regulatory delays or government regulation generally, the 
      company's ability to obtain or maintain patent and other proprietary 
      intellectual protection, and competition in general. Forward-looking 
      statements speak only as to the date they are made. The Company does not 
      undertake to update forward-looking statements to reflect circumstances 
      or events that occur after the date the forward-looking statements are 
      made.
    
    
      For more information visit Investor Relations at www.pureh20biotech.com.